Atezolizumab-Associated Retiform Purpura
- PMID: 38335060
- DOI: 10.1097/MJT.0000000000001665
Atezolizumab-Associated Retiform Purpura
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Georgesen C, Fox LP, Harp J. Retiform purpura: a diagnostic approach. J Am Acad Dermatol. 2020;82:783–796.
-
- Alsarheed A, Cobos GA, Cornejo CM, et al. An approach to retiform purpura for the Inpatient dermatologist. Curr Dermatol Rep. 2019;8:245–257.
-
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
-
- Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rhematol. 2018;14:569–579.
-
- Marrone KA, Ying W, Naidoo J. Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther. 2016;100:242–251.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources